Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Efficacy and safety of AZD3199, an inhaled ultra long-acting β2-agonist, in patients with COPD

Piotr Kuna, Yavor Ivanov, Vasily Trofimov, Ola Beckman, Thomas Bengtsson, Carin Jorup, Francois Maltais
European Respiratory Journal 2011 38: p868; DOI:
Piotr Kuna
1Autonomous Public Healthcare Unit, Barlicki University Hospital, Lodz, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yavor Ivanov
2Dept of Pulmonology, Medical University Pleven, Pleven, Bulgaria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vasily Trofimov
3Department of Hospital Therapy, Pavlov State Medical University, St. Petersburg, Russian Federation
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ola Beckman
4Research and Development, AstraZeneca R&D, Lund, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Bengtsson
4Research and Development, AstraZeneca R&D, Lund, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carin Jorup
4Research and Development, AstraZeneca R&D, Lund, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francois Maltais
5Centre de Pneumologie, Institut Universitaire de Cardiologie et de Pneumologie de Quebec, Quebec, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Figures

  • Figure1
    • Download figure
    • Open in new tab
    • Download powerpoint
Previous
Back to top
Vol 38 Issue Suppl 55 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Efficacy and safety of AZD3199, an inhaled ultra long-acting β2-agonist, in patients with COPD
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Efficacy and safety of AZD3199, an inhaled ultra long-acting β2-agonist, in patients with COPD
Piotr Kuna, Yavor Ivanov, Vasily Trofimov, Ola Beckman, Thomas Bengtsson, Carin Jorup, Francois Maltais
European Respiratory Journal Sep 2011, 38 (Suppl 55) p868;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Efficacy and safety of AZD3199, an inhaled ultra long-acting β2-agonist, in patients with COPD
Piotr Kuna, Yavor Ivanov, Vasily Trofimov, Ola Beckman, Thomas Bengtsson, Carin Jorup, Francois Maltais
European Respiratory Journal Sep 2011, 38 (Suppl 55) p868;
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo

Jump To

  • Article
  • Figures & Data
  • Info & Metrics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Doxofylline: Efficacy and safety in complex treatment of COPD
  • Clinical efficacy and patients' satisfaction for 100 consequent COPD patients using tiotropium respimat
  • Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in health status in ATTAIN
Show more 96. Bronchodilators in asthma and COPD

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2022 by the European Respiratory Society